SpecialityGeneral Partner at Google Ventures

BiographyBefore joining GV, David spent ten years as chief executive officer and a member of the board of directors at Agios Pharmaceuticals, where he remains as a director. He also served as senior vice president of clinical hematology/oncology at Genentech. David was responsible for numerous successful oncology drug approvals and led the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he also served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Before Genentech, David was the senior vice president of clinical research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkin's lymphoma.